HSV Amplicon Vectors for Gene Delivery to the Nervous System

Gene Therapy of the Central Nervous System: From Bench to Bedside

Volumn , Issue , 2006, Pages 25-43

  Senn, Claudia ^a   Fraefel, Cornel ^a   Breakefield, Xandra O ^b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 57449101280     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012397632-1/50004-6     Document Type: Chapter

References (152)

1. Abe A., Miyanohara A., Friedmann T. Enhanced gene transfer with fusogenic liposomes containing vesicular stomatitis virus G glycoprotein. J. Virol. 1998, 72:6159-6163.
2. Adrover M.F., Guyot-Revol V., Cheli V.T., Blanco C., Vidal R., Alche L., Kornisiuk E., Epstein A.L., Jerusalinsky D. Hippocampal infection with HSV-1-derived vectors expressing an NMDAR1 antisense modifies behavior. Genes Brain Behav. 2003, 2:103-113.
3. Advani S.J., Weichselbaum R.R., Whitley R.J., Roizman B. Friedly fire: redirecting herpes simplex virus-1 for therapeutic applications. Clin. Microbiol. Infect. 2002, 8:551-563.
4. Agudo M., Trejo J.L., Lim F., Avila J., Torres-Aleman I., Diaz-Nido J., Wandosell F. Highly efficient and specific gene transfer to Purkinje cells in vivo using a herpes simplex virus I amplicon. Hum. Gene Ther. 2002, 13:665-674.
5. Banfield B.W., Leduc Y., Esford L., Schubert K., Tufaro F. Sequential isolation of proteoglycan synthesis mutants by using herpes simplex virus as a selective agent: evidence for a proteoglycan-independent virus entry path. J. Virol. 1995, 69:3290-3298.
6. Barrot M., Wallace D.L., Bolanos C.A., Graham D.L., Perrotti L.I., Neve R.L., Chambliss H., Yin J.C., Nestler E.J. Regulation of anxiety and initiation of sexual behavior by CREB in the nucleus accumbens. Proc. Natl. Acad. Sci. USA 2005, 102:8357-8362.
7. Bearer E.L., Breakefield X.O., Schuback D., Reese T.S., LaVail J.H. Retrograde axonal transport of herpes simplex virus: evidence for a single mechanism and a role for tegument. Proc. Natl. Acad. Sci. USA 2000, 97:8146-8150.
8. Berns K.I., Linden R.M. The cryptic life style of adeno-associated virus. Bioessays 1995, 17:237-245.
9. Bowers W.J., Chen X., Guo H., Frisina D.R., FederoffH.J., Frisina R.D. Neurotrophin-3 transduction attenuates cisplatin spiral ganglion neuron ototoxicity in the cochlea. Mol. Ther. 2002, 6:12-18.
10. Bowers W.J., Mastrangelo M.A., Stanley H.A., Casey A.E., Milo L.J.J., FederoffH.J. HSV amplicon-mediated Abeta vaccination in Tg2576 mice: differential antigen-specific immune responses. Neurobiol. Aging 2005, 26:393-407.
11. Bragg D.C., Camp S.M., Kaufman C.A., Wilbur J.D., Boston H., Schuback D.E., Hanson P.I., Sena-Esteves M., Breakefield X.O. Perinuclear biogenesis of mutant torsinA inclusions in cultured cells infected with tetracycline-regulated herpes simplex virus type 1 amplicon vectors. Neuroscience 2004, 125:651-661.
12. Brooks A.I., Cory-Slechta D.A., Bowers W.J., Murg S.L., FederoffH.J. Perinuclear biogenesis of mutant torsin A inclusions in cultured cells infected with totracycline-regulated herpes simplex virus type 1 amplicon vecto. Neuroscience 2000, 125:651-661.
13. Brooks A.I., Cory-Slechta D.A., Bowers W.J., Murg S.L., FederoffH.J. Enhanced learning in mice parallels vector-mediated nerve growth factor expression in hippocampus. Hum. Gene Ther. 2000, 11:2341-2352.
14. Bujold M., Caron N., Camiran G., Mukherjee S., Allen P.D., Tremblay J.P., Wang Y. Autotransplantation in mdx mice of mdx myoblasts genetically corrected by an HSV-1 amplicon vector. Cell Transplant. 2002, 11:759-767.
15. Carnicero E., Knipper M., Tan J., Alonso M.T., Schimmang T. Herpes simplex virus type 1-mediated transfer of neurotrophin-3 stimulates survival of chicken auditory sensory neurons. Neurosci. Lett. 2002, 321:149-152.
16. Chiocca E.A. Oncolytic viruses. Nature 2002, 2:938-950.
17. Connolly S.A., Landsburg D.J., CarfiA., Wiley D.C., Eisenberg R.J., Cohen G.H. Structure-based analysis of the herpes simplex virus glycoprotein D binding site present on herpesvirus entry mediator HveA (HVEM). J. Virol. 2002, 76:10894-10904.
18. Connolly S.A., Landsburg D.J., CarfiA., Whitbeck J.C., Zuo Y., Wiley D.C., Cohen G.H., Eisenberg R.J. Potential nectin-1 binding site on herpes simplex virus glycoprotein d. J. Virol. 2005, 79:1282-1295.
19. Cortés M.L., Bakhenist C.J., DiMaria M.W., Kastan M.B., Breakefield X.O. HSV-1 amplicon vector-mediated expression of ATM cDNA and correction of the ataxia-telangiectasia cellular phenotype. Gene Ther. 2003, 10:1321-1327.
20. Costantini L.C., Jacoby D.R., Wang S., Fraefel C., Breakefield X.O., Isacson O. Gene transfer to the nigrostriatal system by hybrid herpes simplex virus/adeno-associated virus amplicon vectors. Hum. Gene Ther. 1999, 10:2481-2494.
21. Dalrymple M.A., McGeoch D.J., Davison A.J., Preston C.M. DNA sequence of the herpes simplex virus type 1 gene whose product is responsible for transcriptional activation of immediate early promoters. Nucl. Acid Res. 1985, 13:7865-7879.
22. Delman K.A., Zager J.S., Bennett J.J., Malhotra S., Ebright M.I., McAuliffe P.F., Halterman M.W., FederoffH.J., Fong Y. Efficacy of multiagent herpes simplex virus amplicon-mediated immunotherapy as adjuvant treatment for experimental hepatic cancer. Ann. Surg. 2002, 236:337-342.
23. Derby M.L., Sena-Esteves M., Breakefield X.O., Corey D.P. Gene transfer of lacZ into the mammalian and amphibian inner ears: a comparison study of three viral vectors. Hearing Res. 1999, 134:1-8.
24. Desai P., Person S. Incorporation of the green fluorescent protein into the herpes simplex virus type 1 capsid. J. Virol. 1998, 72:7563-7568.
25. Dilber M.S., Phelan A., Aints A., Mohamed A.J., Elliott G., Edvard Smith C.I., O'Hare P Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22. Gene Ther. 1999, 6:12-21.
26. Elliott G., O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 1997, 88:223-233.
27. Elliott G., O'Hare P. Intercellular trafficking of VP22-GFP fusion proteins. Gene Ther. 1999, 6:149-151.
28. Elliott G., O'Hare P. Live-cell analysis of a green fluorescent protein-tagged herpes simplex virus infection. J. Virol. 1996, 73:4110-4119.
29. Epstein A.L., Manservigi R. Herpesvirus/retrovirus chimeric vectors. Curr. Gene Ther. 2004, 4:409-416.
30. Fotaki M.E., Pink J.R., Mous J. Tetracycline-responsive gene expression in mouse brain after amplicon-mediated gene transfer. Gene Ther. 1997, 4:901-908.
31. Fraefel C., Jacoby D.R., Lage C., Hilderbrand H., Chou J.Y., Alt F.W., Breakefield X.O., Majzoub J.A. Gene transfer into hepatocytes mediated by helper virus-free HSV/AAV hybrid vectors. Mol. Med. 1997, 3:813-825.
32. Fraefel C., Mendes-Madeira A., Mabon O., Lefebvre A., Le Meur G., Ackermann M., Moullier P., Rolling F. In vivo gene transfer to the rat retina using herpes simplex virus type 1 (HSV-1)-based amplicon vectors. Gene Ther. 2005, 12:1283-1288.
33. Fraefel C., Song S., Lim F., Lang P., Yu L., Wang Y., Wild P., Geller A. Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J. Virol. 1996, 70:7190-7197.
34. Frampton A.R.J., Goins W.F., Nakano K., Burton E.A., Glorioso J.C. HSV trafficking and development of gene therapy vectors with applications in the nervous system. Gene Ther. 2005, 12:891-901.
35. Freundlieb S., Schirra-Muller C., Bujard H. A tetracycline controlled activation/repression system with increased potential for gene transfer into mammalian cells. J. Gene Med. 1999, 1:4-12.
36. Fruh K., Ahn K., Djaballah H., Sempe P., can Endert P.M., Tampe R., Peterson P.A., Yang Y. A viral inhibitor of peptide transporters for antigen presentation. Nature 1995, 375:415-418.
37. Geller A.I., Keyomarski K., Bryan J., Pardee A.B. An efficient deletion mutant packaging system for defective HSV-1 vectors; potential applications to neuronal physiology and human gene therapy. Proc. Natl. Acad. Sci. USA 1990, 87:8950-8954.
38. Grandi P., Spear M., Breakefield X.O., Wang S. Targeting HSV amplicon vectors. Methods 2004, 33:179-186.
39. Grandi P., Wang S., Schuback D., Krasnykh V., Spear M., Curiel D., Manservigi R., Breakefield X.O. HSV-1 virions engineered for specific binding to cell surface receptor. Mol. Ther. 2004, 9:419-427.
40. Grunewald K., Desai P., Winkler D.C., Heymann J.B., Belnap D.M., Baumeister W., Steven A. Three-dimensional structure of herpes simplex virus from cryo-electron tomography. Science 2003, 302:1396-1398.
41. Hammerschmidt W., Sugden B. Epstein-Barr virus sustains Burkitt's lymphomas and Hodgkin's disease. Trends Mol. Med. 2004, 10:331-336.
42. Hampl J.A., Camp S.M., Mydlarz W.K., Hampl M., Ichikawa T., Chiocca E.A., Louis D.N., Sena-Esteves M., Breakefield X.O. Potentiated gene delivery to tumor using herpes simplex virus/Epstein Barr/RV tribrid amplicon vectors. Hum. Gene Ther. 2003, 14:611-626.
43. Harvey B.K., Chang C.F., Chiang Y.H., Bowers W.J., Morales M., Hoffer B.J., Wang Y., FederoffH.J. HSV amplicon delivery of glial cell line-derived neurotrophic factor is neuroprotective against ischemic injury. Exp. Neurol. 2003, 183:47-55.
44. Heilbronn R., Burkel A., Stephan S., zur Hausen H. The adeno-associated virus rep gene suppresses herpes simplex virus-induced DNA amplification. J. Virol. 1990, 64:3012-3018.
45. Heister T., Heid I., Ackermann M., Fraefel C. Herpes simplex virus type 1/adeno-associated virus hybrid vectors mediate site-specific integration at the adeno-associated virus preintegration site, AAVS1, on human chromosome 19. J. Virol. 2002, 76:7163-7173.
46. Herrlinger U., Jacobs A., Quinones A., Woiciechowsky C., Sena-Esteves M., Rainov N.G., Fraefel C., Breakefield X.O. Helper virus-free herpes simplex virus type 1 amplicon vectors for granulocyte-macrophage colony-stimulating factor-enhanced vaccination therapy for experimental glioma. Hum. Gene Ther. 2000, 11:1429-1438.
47. Ho D.Y., McLaughlin J.R., Sapolsky R.M. Inducible gene expression from defective herpes simplex virus vectors using the tetracycline responsive promoter system. Brain Res. Mol. Brain Res. 1996, 41:200-209.
48. Ho D.Y., Mocarski E.S., Sapolsky R.M. Altering central nervous system physiology with a defective herpes simplex virus vector expressing the glucose transporter gene. Proc. Natl. Acad. Sci. USA 1993, 90:3655-3659.
49. Ho I.A., Hui K.M., Lam P.Y. Glioma-specific and cell cycle-regulated herpes simplex virus type 1 amplicon viral vector. Hum. Gene Ther. 2004, 15:495-508.
50. Homa F.L., Brown J.C. Capsid assembly and DNA packaging in herpes simplex virus. Rev. Med. Virol. 1997, 7:107-122.
51. Horsburgh B.C., Hubinette M.M., Tufaro F. Genetic manipulation of herpes simplex virus using bacterial artificial chromosomes. Methods Enzymol. 1999, 306:337-352.
52. Hoshi M., Harada A., Kawase T., Uyemura K., Yazaki T. Antitumoral effects of defective herpes simplex virus-mediated transfer of tissue inhibitor of metalloroteinases-2 gene in malignant glioma U87 in vitro: consequences for anti-cancer gene therapy. Cancer Gene Ther. 2000, 7:799-805.
53. Howarth M., Takao K., Hayashi Y., Ting A.Y. Targeting quantum dots to surface proteins in living cells with biotin ligase. Proc. Natl. Acad. Sci. USA 2005, 102:7583-7588.
54. Huang C.Y., Brandt C.R. Rapid in vivo isolation of gene expression elements using and HSV amplicon system. J. Virol. Meth. 2003, 113:1-12.
55. Ichikawa T., Hogemann D., Saeki Y., Tyminski E., Terada K., Weissleder R., Chiocca E.A., Basilion J.P. MRI of transgene expression: correlation of therapeutic gene expression. Neoplasia 2002, 4:523-530.
56. Inoue R., Moghaddam K.A., Ranashinghe M., Saeki Y., Chiocca E.A., Wade-Martins R. Infectious delivery of the 132 kb CDKN2A/CDKN2B genomic DNA region results in correctly spliced gene expression and growth suppression in glioma cells. Gene Ther. 2004, 11:1195-1204.
57. Izumi K.M., Stevens J.G. Molecular and biological characterization of a herpes simplex type 1 (HSV-1) neuroinvasiveness gene. J. Exp. Med. 1990, 172:487-496.
58. Jacobs A.H., Winkeler A., Hartung M., Slack M., Dittmar C., Kummer C., Knoess C., Galldiks N., Vollmar S., Wienhard K., Heiss W.D. Improved herpes simplex virus type 1 amplicon vectors for proportional coexpression of positron emission tomography marker and therapeutic genes. Hum. Gene Ther. 2003, 14:277-297.
59. Jarnagin W.R., Zager J.S., Klimstra D., Delman K.A., Malhotra S., Ebright M., Little S., DeRubertis B., Stanziale S.F., Hezel M., FederoffH., Fong Y. Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection. Cancer Gene Ther. 2003, 10:215-223.
60. Jin B.K., Belloni M., Conti B., FederoffH.J., Starr R., Son J.H., Baker H., Joh T.H. Prolonged in vivo gene expression driven by a tyrosine hydroxylase promoter in a defective herpes simplex virus amplicon vector. Hum. Gene Ther. 1996, 7:2015-2024.
61. Johnston K.M., Jacoby D., Pechan P., Fraefel C., Borghesani P., Schuback D., Dunn R., Smith F., Breakefield X.O. HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells. Hum. Gene Ther. 1997, 8:359-370.
62. Jonker H.R., Wechselberger R.W., Boelens R., Folkers G.E., Kaptein R. Structural properties of the promiscuous VP16 activation domains. Biochemistry 2005, 44:827-839.
63. Kaneda Y., Twai K., Uchida T. Increased expression of DNA cointroduced with nuclear protein in adult rat liver. Science 1989, 243:375-378.
64. Kaplitt M.G., Kwong A.D., Kleopoulos S.P., Mobbs C.V., Rabkin S.D., PfaffW.D. Preproenkephalin promoter yield regionspecific and long-term expression in adult brain after in viro gene transfer via a defective herpes simplex via vector. Proc. Natl. Acad. Sci. USA 1994, 91:8979-8983.
65. Kwong A.D., Frenkel N. The herpes simplex virus amplicon. IV. Efficient expression of a chimeric chicken ovalbumin gene amplified within defective virus genomes. Virology 1985, 142:421-425.
66. Lam P., Hui K.M., Wang Y., Allen P.A., Louis D.N., Yuan C.J., Breakefield X.O. Dynamics of transgene expression in human glioblastoma cells mediated by herpes simplex virus/adeno-associated virus amplicon vectors. Hum. Gene Ther. 2002, 13:2147-2159.
67. Lamigeon C., Prod'Hon C., De Frias V., Michoudet C., Jacquemont B. Enhancement of neuronal protection from oxidative stress by glutamic acid decarboxylase delivery with a defective herpes simplex virus vector. Exp. Neurol. 2003, 184:381-392.
68. Laquerre S., Anderson D.B., Stolz D.B., Glorioso J.C. Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells. J. Virol. 1998, 72:9683-9697.
69. Laxman B., Hall D.E., Bhojani M.S., Hamstra D.A., Chenevert T.L., Ross B.D., Rehemtulla A. Noninvasive realtime imaging of apoptosis. Proc. Natl. Acad. Sci. USA 2002, 99:16551-16555.
70. Lim F., Hartley D., Starr P., Lang P., Song S., Yu L., Wang Y., Geller A.I. Generation of high-titer defective HSV-1 vectors using an IE2 deletion mutant and quantitative study of expression in cultured cortical cells. BioTechniques 1996, 20:458-469.
71. Linden R.M., Ward P., Giraud C., Winocour E., Berns K.I. Site-specific integration by adeno-associated virus. Proc. Natl. Acad. Sci. USA 1996, 93:11288-11294.
72. LogvinoffC., Epstein A.I. A novel approach for herpes simplex virus type 1 amplicon vector production, using the CreloxP recombination system to remove helper virus. Hum. Gene Ther. 2001, 12:161-167.
73. Lu B., FederoffH.J. Herpes simplex virus type 1 amplicon vectors with glucocorticoid-inducible gene expression. Hum. Gene Ther. 1995, 6:419-428.
74. Maguire-Zeiss K.A., Bowers W.J., FederoffH.J. HSV vector-mediated gene delivery to the central nervous system. Curr. Opin. Mol. Ther. 2001, 3:482-490.
75. Manoj S., Jogger C.R., Myscofski D., Yoon M., Spear P.G. Mutations in herpes simplex virus glycoprotein D that prevent cell entry via nectins and alter cell tropism. Proc. Natl. Acad. Sci. USA 2004, 101:12414-12421.
76. Markert J.M., Medlock M.D., Rabkin S.D., Gillespie G.Y., Todo T., Hunter W.D., Plamer C.A., Feigenbaum F., Tornatore C., Tufaro F., Martuza R.L. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 2000, 7:867-874.
77. Marsh D.R., Dekaban G.A., Tan W., Strathdee C.A., Weaver L.C. Herpes simplex viral and amplicon vector-mediated gene transfer into glia and neurons in organotypic splinal cord and dorsal root ganglion cultures. Mol. Ther. 2000, 1:464-478.
78. McKee, T., Grandi, P., Mok, W., Alexandrakis, G., Boucher, Y., Breadefield, X.O. and Jain, R.K. Collagen degradation augments oncolytic herpesvirus therapy of solid tumors by improving viral vector distribution, submitted.
79. McKnight S., Tjian R. Transcriptional selectivity of viral genes in mammalian cells. Cell 1986, 46:795-805.
80. Messerli S.M., Prabhakar S., Tang Y., Shah K., Cortes M.L., Murthy V., Weissleder R., Breakefield X.O., Tung C.-H. A novel method for imaging apoptosis using a caspase-1 near-infrared fluorescent probe. Neoplasia 2004, 6:95-105.
81. Mitchell B.M., Bloom D.C., Cohrs R.J., Gilden D.H., Kennedy P.G. Herpes simplex virus-1 and varicella-zoster virus latency in ganglia. J. Neurovirol. 2003, 9:194-204.
82. Muller L., Saydam O., Saeki Y., Heid I., Fraefel C. Gene transfer into hepatocytes mediated by herpes simplex virus-Epstein-Barr virus hybrid amplicons. J. Virol. Methods 2005, 123:65-72.
83. Nakano K., Asano R., Tsumoto K., Kwon H., Goins W.F., Kumagai I., Cohen J.B., Glorioso J.C. Herpes simplex virus targeting to the EGF receptor by a gD-specific soluble bridging molecule. Mol. Ther. 2005, 11:617-626.
84. Neill J.C., Sarkisian M.R., Wang Y., Liu Z., Yu L., Tandon P., Zhang G., Holmes G.L., Geller A.I. Enhanced auditory reversal learning by genetic activation of protein kinase C in small groups of rat hippocampal neurons. Brain Res. Mol. Brain Res. 2001, 93:127-136.
85. Nony P., Tessier J., Chadeuf G., Ward P., Giraud A., Dugast M., Linden R.M., Moullier P., Salvetti A. Novel cis-acting replication element in the adeno-associated virus type 2 genome is involved in amplification of integrated rep-cap sequences. J. Virol. 2001, 75:9991-9994.
86. Oehmig A., Fraefel C., Breakefield X.O., Ackermann M. Herpes simplex virus type 1 amplicons and their hybrid virus partners, EBV, AAV, and retrovirus. Curr. Gene Ther. 2004, 4:385-408.
87. Olschowka J.A., Bishop G.A., Hurley S.D., Mastrangelo M.A., FederoffH.J. Helper-free HSV-1 amplicons elicit a markedly less robust innate immune response in the CNS. Mol. Ther. 2003, 7:218-227.
88. Olson V.G., Zabetian C.P., Bolanos C.A., Edwards S., Barrot M., Eisch A.J., Hughes T., Self D.W., Neve R.L., Nestler E.J. Regulation of drug reward by cAMP response element-binding protein: evidence for two functionally distinct subregions of the ventral tegmental area. J. Neurosci. 2005, 25:5553-5562.
89. Ozelius L.J., Hewett J., Page C., Bressman S., Kramer P., Shalish C., de Leon D., Brin M., Raymond D., Corey D.P., Fahn S., Risch N., Buckler A., Gusella J.F., Breakefield X.O. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat. Genet. 1997, 17:40-48.
90. Pechan P., Herrlinger U., Aghi M., Jacobs A., Breakefield X.O. Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas. J. Gene Med. 1999, 1:176-185.
91. Persichetti F., Trettel F., Huang C.C., Fraefel C., Timmers H.T., Gusella J.F., MacDonald M.E. Mutant huntingtin forms in vivo complexes with distinct context-dependent conformations of the polyglutamine segment. Neurobiol. Dis. 1999, 6:364-375.
92. Phelan A., Elliott G., O'Hare P. Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat. Biotech. 1998, 16:440-443.
93. Philpott N.J., Giraud-Wali C., Dupuis C., Gomos J., Hamilton H., Berns K.I., Falck-Pedersen E. Efficient integration of recombinant adeno-associated virus DNA vectors requires a p5-rep sequence in cis. J. Virol. 2002, 76:5411-5421.
94. Philpott N.J., Gomos H., Berns K.I., Flack-Pedersen E. A p5 integration efficiency element mediates Rep-dependent integration into AAVS1 at chromosome 19. Proc. Natl. Acad. Sci. USA 2002, 99:12381-12385.
95. Pin R.H., Reinblatt M., Bowers W.J., FederoffH.J., Fong Y. Herpes simplex virus amplicon delivery of a hypoxia-inducible angiogenic inhibitor blocks capillary formation in hepatocellular carcinoma. J. Gastrointest. Surg. 2004, 8:812-822.
96. Praetorius M., Knipper M., Schick B., Tan J., Limberger A., Carnicero E., Alonso M.T., Schimmang T. A novel vestibular approach for gene transfer into the inner ear. Audiol. Neurootol. 2002, 7:324-334.
97. Preston C.M. Repression of viral transcription during herpes simplex virus latency. J. Gen. Virol. 2000, 81:1-19.
98. Qi J., Shackelford R., Manuszak R., Cheng D., Smith M.C., Link C.J., Wang S. Functional expression of ATM gene carried by HSV amplicon vector in vitro and in vivo. Gene Ther. 2004, 11:25-33.
99. Rainov N.G., Sena-Esteves M., Fraefel C., Dobberstein K.U., Chiocca E.A., Breakefield X.O. A chimeric fusion protein of cytochrome CYP4B1 and green fluorescent protein for detection of pro-drug activating gene delivery and for gene therapy in malignant glioma. Gene Therapy of Cancer 1998, Vol. 61:393-403. Plenum Press, New York. P. Walden (Ed.).
100. Rajcani J., Andrea V., Ingeborg R. Peculiarities of herpes simplex virus (HSV) transcription: an overview. Virus Genes 2004, 28:293-310.
101. Recchia A., Parks R.J., Lamartina S., Toniatti C., Pieroni L., Palombo F., Ciliberto G., Graham F.L., Cortese R., La Monica N., Colloca S. Site-specific integration mediated by a hybrid adenovirus-adeno/associated virus. Proc. Natl. Acad. Sci. USA 1999, 96:2615-2620.
102. Reisman D., Yates J., Sugden B. A putative origin of replication of plasmids derived from Epstein-Barr virus is composed of two cis-acting components. Mol. Biol. Cell 1985, 5:1822-1832.
103. Roizman B., Pellett P.E. The family herpesvirdai: a brief introduction. Fields Virology 2001, Vol. 2:2231-2295. Lippencott-Raven, Philadelphia. 3rd ed. D.M. Knipe, P.M. Howley (Eds.).
104. Rotman G., Shiloh Y. ATM: a mediator of multiple responses to genotoxic stress. Oncogene 1999, 18:6135-6144.
105. Rueger M.A., Winkeler A., Miletic H., Kaestle C., Richter R., Schneider G., Hilker R., Heneka M.T., Ernestus R.I., Hampl J.A., Fraefel C., Jacobs A.H. Variability in infectivity of primary cell cultures of human brain tumors with HSV-1 amplicon vectors. Gene Ther. 2005, 12:588-596.
106. Rumpel S., LeDoux J., Zador A., Malinow R. Postsynaptic receptor trafficking underlying a form of associative learning. Science 2005, 308:83-88.
107. Saeki Y., Fraefel C., Ichikawa T., Breakefield X.O., Chiocca E.A. Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol. Ther. 2001, 3:591-601.
108. Saeki Y., Ichikawa T., Saeki A., Chiocca E.A., Tobler K., Ackermann M., Breakefield X.O., Fraefel C. Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum. Gene Ther. 1998, 9:2787-2794.
109. Saeki Y., Matsumoto N., Nakano Y., Mori M., Awai K., Kaneda Y. Development and characterization of cationic liposomes conjugated with HSJ (Sendai virus): reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. Hum. Gene Ther. 1997, 8:2133-2141.
110. Sandler V., Wang S., Angelo K., Lo H., Breakefield X.O., Clapham D.E. Modified herpes simplex virus delivery of enhanced GFP into the central nervous system. J. Neurosci. Methods 2002, 121:211-219.
111. Seijffers R., Woolf C.J. Utilization of an HSV-based amplicon vector encoding the axonal marker hPLAP to follow neurite outgrowth in cultured DRG neurons. J. Neurosci. Methods 2004, 132:169-176.
112. Sena-Esteves M., Hampl J.A., Camp S.M., Breakefield X.O. Generation of stable retrovirus packaging cell lines after transduction with herpes simplex virus hybrid amplicon vectors. J. Gene Med. 2002, 4:229-239.
113. Sena-Esteves M., Saeki Y., Camp S., Chiocca E.A., Breakefield X.O. Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons. J. Virol. 1999, 73:10426-10439.
114. Severini A., Morgan A.R., Tovell D.R., Tyrrell D.L. Study of the structure of replicative intermediates of HSV-1 DNA by pulsed-field gel electrophoresis. Virology 1994, 200:428-435.
115. Shah K., Bureau E., Kim D.E., Yang K., Tang Y., Weissleder R., Breakefield X.O. Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. Ann. Neurol. 2004, 57:34-41.
116. Shah K., Tang Y., Breakefield X.O., Weissleder R. Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo. Oncogene 2003, 22:6865-6872.
117. Shieh M.T., Wudunn D., Montgomery R.I., Esko J.D., Spear P.G. Cell surface receptors for herpes simplex virus are heparan sulfate proteoglycans. J. Cell Biol. 1992, 116:1273-1281.
118. Smith A.E. Viral vectors in gene therapy. Annu. Rev. Microbiol. 1995, 49:807-838.
119. Smith R.L., Geller A.I., Escudero K.W., Wilcox C.L. Long-term expression in sensory neurons in tissue culture from herpes simplex virus type 1 (HSV-1) promoters in an HSV-1-derived vector. J. Virol. 1995, 69:4593-4599.
120. Sodeik B., Ebersold M.W., Helenius A. Microtubule-mediated transport of incoming herpes simplex virus 1 capsids to the nucleus. J. Cell Biol. 1997, 136:1007-1021.
121. Song S., Wang Y., Bak S.Y., Lang P., Ullrey D., Neve R.L., O'Malley K.L., Geller A.I. An HSV-1 vector containing the rat tyrosine hydroxylase promoter enhances both long-term and cell type-specific expression in the midbrain. J. Neurochem. 1997, 68:1792-1803.
122. Sosinsky G.E., Gaietta G.M., Hand G., Deerinck T.J., Han A., Mackey M., Adams S.R., Bouwer J., Tsien R.Y., Ellisman M.H. Tetracysteine genetic tags complexed with biarsenical ligands as a tool for investigating gap junction structure and dynamics. Cell Commun. Adhes. 2003, 10:181-186.
123. Spaete R., Frenkel N. The herpes virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector. Cell 1982, 30:295-304.
124. Spaete R.R., Frenkel N. The herpes simplex virus amplicon: analyses of cis-acting replication functions. Proc. Natl. Acad. Sci. USA 1985, 82:694-698.
125. Spear P.G. Herpes simplex virus: receptors and ligands for cell entry. Cell Microbiol. 2004, 6:401-410.
126. Spear P.G., Eisenberg R.J., Cohen G.H. Three classes of cell surface receptors for alpha herpes virus entry. Virology 2000, 275:1-8.
127. Stavropoulos T.A., Strathdee C.A. An enhanced packaging system for helper-dependent herpes simplex virus vectors. J. Virol. 1998, 72:7137-7143.
128. Stevens J.G. Latent herpes simplex virus and the nervous system. Curr. Top. Microbiol. Immunol. 1975, 70:31-50.
129. Strathdee C.A., McLeod M.R. A modular set of helper-dependent herpes simplex virus expression vectors. Mol. Ther. 2000, 1:479-485.
130. Sun M., Zhang G.R., Kong L., Holmes C., Wang X., Zhang W., Goldstein D.S., Geller A.I. Correction of a rat model of Parkinson's disease by coexpression of tyrosine hydroxylase and aromatic amino acid decarboxylase from a helper virus-free herpes simplex virus type 1 vector. Hum. Gene Ther. 2003, 14:415-424.
131. Tannous, B.A., Grinn, T., Weissleder, R. and Breakefield, X.O. Metabolic biotinylation of receptors in mammalian cells for tumor imaging in vivo, in preparation.
132. Toda M., Martuza R.L., Rabkin S.D. Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expression granulocyte-macrophage colony-stimulating factor. Mol. Ther. 2000, 2:324-329.
133. Tsien R.Y. Building and breeding molecules to spy on cells and tumors. FEBS Lett. 2005, 579:927-932.
134. Turner A., Bruun B., Minson T., Browne H. Glycoproteins gB, gD, and gHgL of herpes simplex virus type 1 are necessary and sufficient to mediate membrane fusion in a Cos cell transfection system. J. Virol. 1998, 72:873-875.
135. van Roessel P., Brand A.H. Imaging into the future: visualizing gene expression and protein interactions with fluorescent proteins. Nat. Cell Biol. 2002, 4:E15-E20.
136. Vicario I., Schimmang T. Transfer of FGF-2 via HSV-1-based amplicon vectors promotes efficient formation of neurons from embryonic stem cells. J. Neurosci. Methods 2003, 123:55-60.
137. Wade-Martins R., Saeki Y., Chiocca E.A. Infectious delivery of a 135-kb LDLR genomic locus leads to regulated complementation of low-density lipoprotein receptor deficiency in human cells. Mol. Ther. 2003, 7:604-612.
138. Wade-Martins R., Smith E.R., Tyminski E., Chiocca E.A., Saeki Y. An infectious transfer and expression system for genomic DNA loci in human and mouse cells. Nat. Biotechnol. 2001, 19:1067-1070.
139. Wang S., Petravicz J., Breakefield X.O. Single HSV-amplicon vector mediates drug-induced gene expression via dimerizer system. Mol. Ther. 2003, 7:790-800.
140. Wang S., Qi J., Smith M.C., Link C.J. Antitumor effects on human melanoma xenografts of an amplicon vector transducing the herpes thymidine kinase gene followed by ganciclovir. Cancer Gene Ther. 2002, 9:1-8.
141. Wang S., Vos J.-M. A hybrid herpes virus infectious vector based on Epstein-Barr virus and herpes simplex virus type 1 for gene transfer into human cells in vitro and in vivo. J. Virol. 1996, 70:8422-8430.
142. Wang S.W., Mu X., Bowers W.J., Klein W.H. Retinal ganglion cell differentiation in cultured mouse retinal explants. Methods 2002, 28:448-456.
143. Wang X., Kong L., Zhang G.R., Sun M., Geller A.I. A preproenkephalin-neurofilament chimeric promoter in a helper virus-free herpes simplex virus vector enhances long-term expression in the rat striatum. Neurobiol. Dis. 2004, 16:596-603.
144. Wang Y., Mukherjee S., Fraefel C., Breakefield X.O., Allen P.D. Herpes simplex virus type 1 amplicon vector-mediated gene transfer to muscle. Hum. Gene Ther. 2002, 13:261-273.
145. Wang Y., Yu L., Geller A.I. Diverse stabilities of expression in the rat brain from different cellular promoters in a helper virus-free herpes simplex virus type 1 vector system. Hum. Gene Ther. 1999, 10:1763-1771.
146. Willis R.A., Bowers W.J., Turner M.J., Fisher T.L., Abdul-Alim C.S., Howard D.F., FederoffH.J., Lord E.M., Frelinger J.G. Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice. Hum. Gene Ther. 2001, 12:1867-1879.
147. Wysocka J., Herr W. The herpes simplex virus VP16-induced complex: the makings of a regulatory switch. Trends Biochem. Sci. 2003, 28:294-304.
148. Xing W., Baylink D., Kesavan C., Mohan S. HSV-1 amplicon-mediated transfer of 128-kb BMP-2 genomic locus stimulates osteoblast differentiation in vitro. Biochem. Biophys. Res. Commun. 2004, 319:781-786.
149. Yoon M., Spear P.G. Random mutagenesis of the gene encoding a viral ligand for multiple cell entry receptors to obtain viral mutants altered for receptor usage. Proc. Natl. Acad. Sci. USA 2004, 101:17252-17257.
150. Yoon M., Zago A., Shukla D., Spear P.G. Mutations in the N termini of herpes simplex virus type 1 and 2 gDs alter functional interactions with the entry/fusion receptors HVEM, nectin-2, and 3-O-sulfated heparan sulfate but not with nectin-1. J. Virol. 2003, 77:9221-9231.
151. Zager J.S., Delman K.A., Malhotra S., Ebright M.I., Bennett J.J., Kates T., Halterman M., FederoffH., Fong Y. Combination vascular delivery of herpes simplex oncolytic viruses and amplicon mediated cytokine gene transfer is effective therapy for experimental liver cancer. Mol. Med. 2001, 7:561-568.
152. Zhang Y., Hong Y., Bounhar Y., Blacker M., Roucou X., Tounekti O., Vereker E., Bowers W.J., FederoffH.J., Goodyer C.G., LeBlanc A. p75 neurotrophin receptor protects primary cultures of human neurons against extracellular amyloid beta peptide cytotoxicity. J. Neurosci. 2003, 23:7385-7394.